Biological impact of superparamagnetic iron oxide nanoparticles for magnetic particle imaging of head and neck cancer cells

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 5025-5040

  Lindemann, Antje ^a   Lüdtke Buzug, Kerstin ^b   Fräderich, Bianca M ^a   Gräfe, Ksenija ^b   Pries, Ralph ^a   Wollenberg, Barbara ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Biomedical imaging; Cell labeling; Cytotoxicity; HNSCCs; Iron oxide nanoparticles

Indexed keywords

FERUCARBOTRAN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; MAGNETITE NANOPARTICLE; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; BIOCOMPATIBILITY; CANCER CELL; CELL COUNT; CELL GROWTH; CELL LABELING; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CYTOKINE RELEASE; CYTOKINE RESPONSE; CYTOTOXICITY; FLOW CYTOMETRY; GROWTH INHIBITION; HEAD AND NECK CANCER; HYDRODYNAMICS; IMAGE ANALYSIS; IMAGE QUALITY; IMAGING; MAGNETIC PARTICLE IMAGING; OXIDATIVE STRESS; PARTICLE SIZE; PHAGOCYTOSIS; CHEMISTRY; DIAGNOSTIC IMAGING; DRUG EFFECTS; HEAD AND NECK TUMOR; HUMAN; METABOLISM; PROCEDURES; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL SURVIVAL; CYTOKINES; DIAGNOSTIC IMAGING; HEAD AND NECK NEOPLASMS; HUMANS; MAGNETITE NANOPARTICLES; REACTIVE OXYGEN SPECIES;

EID: 84908548827     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S63873     Document Type: Article

References (63)

1. Tong L, Zhao M, Zhu S, Chen J. Synthesis and application of superparamagnetic iron oxide nanoparticles in targeted therapy and imaging of cancer. Front Med. 2011;5(4):379-387.
2. Gleich B, Weizenecker J. Tomographic imaging using the nonlinear response of magnetic particles. Nature. 2005;435(7046):1214-1217.
3. Buzug TM, Bringout G, Erbe M, et al. Magnetic particle imaging: introduction to imaging and hardware realization. Z Med Phys. 2012; 22(4):323-334.
4. Weizenecker J, Gleich B, Rahmer J, Dahnke H, Borgert J. Three-dimensional real-time in vivo magnetic particle imaging. Phys Med Biol. 2009;54(5):L1-L10.
5. Sattel TF, Knopp T, Biederer S, et al. Single-sided device for magnetic particle imaging. J Phys D Appl Phys. 2009;42(2).
6. Goodwill PW, Tamrazian A, Croft LR, et al. Ferrohydrodynamic relaxometry for magnetic particle imaging. Appl Phys Lett. 2011;98(26).1
7. Buzug TM. Magnetic Particle Imaging: Principles and Clinical Application. In: Alexiou C, editors. Nanomedicine-Basic and Clinical Application in Diagnostics and Therapy. Vol 2. Erlangen: Karger Publishers; 2011:88-95.
8. Eberbeck D, Wiekhorst F, Wagner S, Trahms L. How the size distribution of magnetic nanoparticles determines their magnetic particle imaging performance. Appl Phys Lett. 2011;98(18).
9. Biederer S, Knopp T, Sattel TF, et al. Magnetization response spectroscopy of superparamagnetic nanoparticles for magnetic particle imaging. J Phys D Appl Phys. 2009;42(20): Article ID 205007.
10. Ai J, Biazar E, Jafarpour M, et al. Nanotoxicology and nanoparticle safety in biomedical designs. Int J Nanomedicine. 2011;6:1117-1127.
11. Jeng HA, Swanson J. Toxicity of metal oxide nanoparticles in mammalian cells. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2006;41(12):2699-2711.
12. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. Science. 2006;311(5761):622-627.
13. Singh N, Jenkins GJ, Asadi R, Doak SH. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev. 2010;1. Epub 2010 Sep 21.
14. Toyokuni S. Iron and carcinogenesis: from Fenton reaction to target genes. Redox Rep. 2002;7(4):189-197.
15. Mahmoudi M, Simchi A, Milani AS, Stroeve P. Cell toxicity of superparamagnetic iron oxide nanoparticles. J Colloid Interface Sci. 2009; 336(2):510-518.
16. Borgert J, Schmidt JD, Schmale I, et al. Fundamentals and applications of magnetic particle imaging. J Cardiovasc Comput Tomogr. 2012;6(3): 149-153.
17. Haegele J, Rahmer J, Gleich B, et al. Magnetic particle imaging: visualization of instruments for cardiovascular intervention. Radiology. 2012;265(3):933-938.
18. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11(1):9-22.
19. Du Y, Lai PT, Leung CH, Pong PW. Design of superparamagnetic nanoparticles for magnetic particle imaging (MPI). Int J Mol Sci. 2013; 14(9):18682-18710.
20. Massart R. Preparation of aqueous magnetic liquids in alkaline and acidic media. IEEE Transactions on Magnetics. 1981;17(2): 1247-1248.
21. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26(18): 3995-4021.
22. Bain BJ. Blood cells: a practical guide. 4th ed. Bain B editor. Malden, Mass: Oxford. Wiley; 2007.
23. Adhikamsetty RK, Jonnalagadda SB. Kinetics and mechanism of prussian blue formation. Bull Chem Soc Ethiop. 2009;23(1):47-54.
24. Xu R. Particle characterization. Light scattering methods. Dordrecht; London: Kluwer Academic; 2000.
25. Mishchenko MI, Travis LD, Lacis AA. Scattering, Absorption, And Emission of Light by Small Particles. Cambridge: Cambridge University Press; 2002.
26. Morris VJ, Kirby AR, Gunning AP. Atomic Force Microscopy for Biologists. 2nd ed. London: Imperial College Press; 2010.
27. Reimer P, Rummeny EJ, Daldrup HE, et al. Clinical results with Resovist: a phase 2 clinical trial. Radiology. 1995;195(2):489-496.
28. Christopher D. Lansford, Reidar Grenman, Henning Bier, et al. Human Cell Culture: Springer Netherlands; 2002.
29. Gilchrist RK, Medal R, Shorey WD, Hanselman RC, Parrott JC, Taylor CB. Selective inductive heating of lymph nodes. Ann Surg. 1957;146(4):596-606.
30. Laurent S, Forge D, Port M, et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev. 2008;108(6):2064-2110.
31. Berkovskii BM, Bashtovoi VG. Magnetic fluids and applications handbook. New York; Wallingford: Begell House; 1996.
32. Ferguson RM, Minard KR, Krishnan KM. Optimization of nanoparticle core size for magnetic particle imaging. J Magn Magn Mater. 2009;321(10):1548-1551.
33. Buzug TM, Borgert Jr. Magnetic particle imaging: a novel SPIO nanoparticle imaging technique. Heidelberg; London: Springer; 2012.
34. Gupta AK, Curtis AS. Surface modified superparamagnetic nanoparticles for drug delivery: interaction studies with human fibroblasts in culture. J Mater Sci Mater Med. 2004;15(4):493-496.
35. Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng. 2006;34(1):23-38.
36. Berry CC, Curtis ASG. Functionalisation of magnetic nanoparticles for applications in biomedicine. J Phys D Appl Phys. 2003;36(13):R198-R206.
37. Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng. 2006;34(1):23-38.
38. Moore A, Marecos E, Bogdanov A, Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology. 2000;214(2):568-574.
39. Berry CC, Wells S, Charles S, Curtis ASG. Dextran and albumin derivatised iron oxide nanoparticles: influence on fibroblasts in vitro. Biomaterials. 2003;24(25):4551-4557.
40. Gamarra LF, Brito GES, Pontuschka WM, Amaro E, Parma AHC, Goya GF. Biocompatible superparamagnetic iron oxide nanoparticles used for contrast agents: a structural and magnetic study. J Magn Magn Mater. 2005;289:439-441.
41. Tassa C, Shaw SY, Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Accounts Chem Res. 2011;44(10):842-852.
42. Martin VM, Siewert C, Scharl A, et al. Immunomagnetic enrichment of disseminated epithelial tumor cells from peripheral blood by MACS. Exp Hematol. 1998;26(3):252-264.
43. Islam T, Harisinghani MG. Overview of nanoparticle use in cancer imaging. Cancer Biomark. 2009;5(2):61-67.
44. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm. 2005;2(3):194-205.
45. Wagner K, Kautz A, Roeder M, et al. Synthesis of oligonucleotide-functionalized magnetic nanoparticles and study on their in vitro cell uptake. Applied Organometallic Chemistry. 2004;18(10):514-519.
46. Moore A, Weissleder R, Bogdanov A Jr. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging. 1997;7(6):1140-1145.
47. Reimer P, Schuierer G, Balzer T, Peters PE. Application of a superparamagnetic iron oxide (Resovist) for MR imaging of human cerebral blood volume. Magn Reson Med. 1995;34(5):694-697.
48. Kopp AF, Laniado M, Dammann F, et al. MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties. Radiology. 1997;204(3):749-756.
49. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol. 2003;13(6):1266-1276.
50. Matuszewski L, Persigehl T, Wall A, et al. Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency. Radiology. 2005;235(1): 155-161.
51. Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C, Corot C. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol. 2004;39(1):56-63.
52. Zolnik BS, Gonzalez-Fernandez A, Sadrieh N, Dobrovolskaia MA. Nanoparticles and the immune system. Endocrinology. 2010;151(2):458-465.
53. Yeh CH, Hsiao JK, Wang JL, Sheu F. Immunological impact of magnetic nanoparticles (Ferucarbotran) on murine peritoneal macrophages. J Nanopart Res. 2010;12(1):151-160.
54. Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C, Corot C. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles-Mechanisms and comparison of Ferumoxides and Ferumoxtran-10. Investigative Radiology. 2004;39(1):56-63.
55. Muller K, Skepper JN, Posfai M, et al. Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyie-macrophages in vitro. Biomaterials. 2007;28(9):1629-1642.
56. Maurer-Jones MA, Bantz KC, Love SA, Marquis BJ, Haynes CL. Toxicity of therapeutic nanoparticles. Nanomedicine (London). 2009; 4(2):219-241.
57. Thomas R, Park IK, Jeong YY. Magnetic iron oxide nanoparticles for multimodal imaging and therapy of cancer. Int J Mol Sci. 2013;14(8): 15910-15930.
58. Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H. MRI of the prostate: clinical relevance and emerging applications. J Magn Reson Imaging. 2011;33(2):258-274.
59. Jain R, Dandekar P, Patravale V. Diagnostic nanocarriers for sentinel lymph node imaging. J Control Release. 2009;138(2):90-102.
60. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348(25):2491-2499.
61. Jain KK. Advances in the field of nanooncology. BMC Med. 2010;8:83.
62. Banobre-Lopez M, Teijeiro A, Rivas J. Magnetic nanoparticle-based hyperthermia for cancer treatment. Rep Pract Oncol Radiother. 2013; 18(6):397-400.
63. Bhirde A, Xie J, Swierczewska M, Chen XY. Nanoparticles for cell labeling. Nanoscale. 2011;3(1):142-153.